The effect of intralesional 5-Fluorouracil Therapeutic Implant (MPI 5003) for treatment of basal cell carcinoma
Authors:
- Bruce H. MillerBMBruce H. Miller
- Hubert T. GreenwayHGHubert T. Greenway
- Judith A. KoperskiJKJudith A. Koperski
- Nicholas LoweNLNicholas Lowe
- Theodore RosenTRTheodore Rosen
- Dennis M. BrownDBDennis M. Brown
- Margaret InuiMIMargaret Inui
- Andrew G. KoreyAKAndrew G. Korey
- Edward E. LuckELEdward E. Luck
- 1 November 1992
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 27 (5) , 723-728
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Biology of basal cell carcinoma (Part II)Journal of the American Academy of Dermatology, 1991
- Biology of basal cell carcinoma (Part I)Journal of the American Academy of Dermatology, 1991
- Intralesional interferon therapy for basal cell carcinomaJournal of the American Academy of Dermatology, 1990
- The effect of intralesional interferon gamma on basal cell carcinomasJournal of the American Academy of Dermatology, 1990
- Topical chemotherapy with 5-fluorouracilJournal of the American Academy of Dermatology, 1981
- Successful treatment of keratoacanthoma with intralesional fluorouracilJournal of the American Academy of Dermatology, 1980
- Treatment of Cutaneous Neoplasms by Intralesional Injections of 5‐Fluorouracil (5‐FU)The Journal of Dermatologic Surgery and Oncology, 1980
- Bowen's disease and 5-fluorouracilJournal of the American Academy of Dermatology, 1979
- Treatment of Basal Cell Carcinoma of the Skin with 5-Fluorouracil OintmentDermatology, 1979
- Intradermal 5-Fluorouracil in the Treatment of Basal Cell Carcinoma of the FaceSouthern Medical Journal, 1976